CRP-ChoP Binding Assay for Rapid Pathogen Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for respiratory tract infections are slow and often incorrect, leading to delayed and inappropriate treatment, which contributes to antimicrobial resistance issues due to the frequent use of broad-spectrum antibiotics.
Innovation Solution
A rapid diagnostic test that uses C-reactive protein (CRP) to specifically bind to phosphorylcholine (ChoP) on the surface of pathogenic respiratory bacteria, employing antibodies to detect and identify these bacteria in biological samples, allowing for specific clinical treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic tests are used to identify respiratory tract pathogens, then treatment can be provided, but the diagnosis is slow and often incorrect leading to delayed and inappropriate treatment
Solution Approach 1:
The invention extracts and detects specific molecular markers (CRP and ChoP) that are uniquely present in pathogenic respiratory infections, separating the detection of true pathogens from commensal bacteria. This extraction of specific diagnostic markers enables rapid and accurate identification without requiring full culture procedures.
Solution Approach 2:
The invention uses C-reactive protein (CRP) as an intermediary marker that binds to phosphorylcholine (ChoP) on the surface of pathogenic bacteria. This intermediary approach allows indirect detection of pathogens through their molecular signatures, providing rapid diagnosis without direct bacterial culture.
2Reliability
If broad-spectrum antibiotics are used frequently to treat respiratory infections, then treatment coverage is ensured, but antimicrobial resistance increases
Solution Approach 1:
The invention enables targeted treatment by identifying the specific pathogen causing infection through detection of CRP-ChoP complexes. This local specificity allows clinicians to prescribe narrow-spectrum antibiotics tailored to the identified pathogen rather than using broad-spectrum agents, thereby maintaining treatment effectiveness while reducing resistance development.
Solution Approach 2:
Instead of using broad-spectrum antibiotics and hoping to cover the pathogen, the invention inverts the approach by first identifying the specific pathogen through molecular markers and then selecting appropriate targeted therapy. This reversal of the traditional empiric treatment approach minimizes unnecessary antibiotic exposure.
3Measurement precision
If it is difficult to distinguish between pathogenic and commensal microorganisms, then appropriate treatment cannot be targeted, but healthcare personnel must make clinical decisions
Solution Approach 1:
The invention employs detection methods that produce visual or measurable signals (such as colorimetric changes in ELISA assays or fluorescent signals) when CRP-ChoP complexes are detected. This transforms the complex immunological interaction into a simple, readable signal that guides clinical decision-making without requiring expert interpretation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid and accurate identification of causative microorganisms, reducing the need for broad-spectrum antibiotics and minimizing antimicrobial resistance by enabling targeted treatment.
Implementation Method 1
CRP binds in a calcium-dependent manner to choline phosphate or phosphorylcholine (ChoP) residues found on C polysaccharide
Implementation Method 2
contacting a substrate comprising a first antibody that specifically binds C-reactive protein (CRP) with the biological sample, contacting the biological sample with a second antibody that specifically binds the pathogenic respiratory bacteria
Data Source
AI summary
The present invention encompasses methods, assays and kits for the detection of pathogenic bacteria in a patient and for the differential diagnosis of pulmonary diseases associated with pathogenic bacteria from pulmonary diseases not associated with pathogenic bacteria.